Product
Y101D
Aliases
Cohort 1 of Y101D, Cohort 2 of Y101D, Cohort 3 of Y101D, Cohort 4 of Y101D, Cohort 5 of Y101D (1 other aliases)
2 clinical trials
2 indications
Indication
Pancreatic AdenocarcinomaClinical trial
A Phase 1, Multicenter, Open-label, Dose-increasing Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of Y101D, a Recombinant Anti-PD-L1 and TGF-β Bispecific Antibody for Injection, in Patients With Metastatic or Locally Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-03-15
Clinical trial
Phase Ib/II Trial of Y101D Combined With Gemcitabine and Albumin Paclitaxel in First-line Treatment of Patients With Advanced Pancreatic CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-30